Merits and pitfalls of genetic testing in a hypertrophic cardiomyopathy clinic.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  The Israel Medical Association journal : IMAJ

• Publication date

  2014-11-01

• Fields of study

  Medicine

• Identifiers
  PMID 25558701
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Reversible heart failure with left ventricular dysfunction in a postpartum woman with familial hypertrophic cardiomyopathy.

  2013cited by this paper
• Genetic Testing for Potentially Lethal, Highly Treatable Inherited Cardiomyopathies/Channelopathies in Clinical Practice

  2011cited by this paper
• In the thick of it: HCM-causing mutations in myosin binding proteins of the thick filament.

  2011cited by this paper
• 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

  2011cited by this paper
• HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA).

  2011cited by this paper
• Structure and Interactions of Myosin-binding Protein C Domain C0

  2011cited by this paper
• The effect of next-generation sequencing technology on complex trait research

  2011cited by this paper
• Sarcomere Protein Gene Mutations in Patients With Apical Hypertrophic Cardiomyopathy

  2011cited by this paper
• 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

  2011cited by this paper
• Microvascular function is selectively impaired in patients with hypertrophic cardiomyopathy and sarcomere myofilament gene mutations.

  2011cited by this paper
• DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model.

  2010cited by this paper
• Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases.

  2010cited by this paper
• Clinical assessment incorporating a personal genome.

  2010cited by this paper
• Hypertrophic cardiomyopathy: the genetic determinants of clinical disease expression

  2008cited by this paper
• Hypertrophic cardiomyopathy: the genetic determinants of clinical disease expression

  2008cited by this paper
• Gene Mutations in Apical Hypertrophic Cardiomyopathy

  2005cited by this paper
• Glycogen storage diseases presenting as hypertrophic cardiomyopathy.

  2005cited by this paper
• Hypertrophic Cardiomyopathy: Distribution of Disease Genes, Spectrum of Mutations, and Implications for a Molecular Diagnosis Strategy

  2003cited by this paper
• Mutation spectrum in a large cohort of unrelated consecutive patients with hypertrophic cardiomyopathy

  2003cited by this paper
• American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice G

  2003cited by this paper
• American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice G

  2003cited by this paper
• Expert consensus document American College of Cardiology / European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy

  2003cited by this paper
• Mutations in cis can confound genotype-phenotype correlations in hypertrophic cardiomyopathy

  2001cited by this paper
• Diagnostic value of electrocardiography and echocardiography for familial hypertrophic cardiomyopathy in genotyped children.

  1998cited by this paper
• Prognostic implications of novel beta cardiac myosin heavy chain gene mutations that cause familial hypertrophic cardiomyopathy.

  1994cited by this paper
• Differences in Clinical Expression of Hypertrophic Cardiomyopathy Associated With Two Distinct Mutations in the β‐Myosin Heavy Chain Gene: A 908Leu→Val Mutation and a 403Arg→gGln Mutation

  1992cited by this paper
• Familial cardiomyopathy with variable hypertrophic and restrictive features and common HLA haplotype.

  1992cited by this paper
• Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy.

  1992cited by this paper
• Familial cardiomyopathy. A review of 11 families.

  1971cited by this paper

• Troponin I – a comprehensive review of its function, structure, evolution, and role in muscle diseases

  2025cites this paper
• Disease mutations in striated muscle myosins

  2020cites this paper
• Principles and Practice of Genetic Counselling for Inherited Cardiac Conditions

  2018cites this paper
• Development of a communication aid for explaining hypertrophic cardiomyopathy genetic test results

  2017cites this paper
• Comparison of current guidelines for primary prevention of sudden cardiac death in hypertrophic cardiomyopathy – is clinical practice consistent ?

  2016cites this paper
• Risk Stratification in Hypertrophic Cardiomyopathy.

  2015cites this paper
• Using whole exome sequencing and bioformatics in the molecular autopsy of a sudden unexplained death syndrome (SUDS) case.

  2015cites this paper